Perspective Begin Period Cash Flow vs Depreciation Analysis

CATX Stock   4.12  0.28  6.36%   
Perspective Therapeutics financial indicator trend analysis is much more than just breaking down Perspective Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Perspective Therapeutics is a good investment. Please check the relationship between Perspective Therapeutics Begin Period Cash Flow and its Depreciation accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Perspective Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Perspective Stock please use our How to Invest in Perspective Therapeutics guide.

Begin Period Cash Flow vs Depreciation

Begin Period Cash Flow vs Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Perspective Therapeutics Begin Period Cash Flow account and Depreciation. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Perspective Therapeutics' Begin Period Cash Flow and Depreciation is -0.09. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Depreciation in the same time period over historical financial statements of Perspective Therapeutics, assuming nothing else is changed. The correlation between historical values of Perspective Therapeutics' Begin Period Cash Flow and Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Perspective Therapeutics are associated (or correlated) with its Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation has no effect on the direction of Begin Period Cash Flow i.e., Perspective Therapeutics' Begin Period Cash Flow and Depreciation go up and down completely randomly.

Correlation Coefficient

-0.09
Relationship DirectionNegative 
Relationship StrengthInsignificant

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Depreciation

Depreciation indicates how much of Perspective Therapeutics value has been used up. For tax purposes Perspective Therapeutics can deduct the cost of the tangible assets it purchases as business expenses. However, Perspective Therapeutics must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.
Most indicators from Perspective Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Perspective Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Perspective Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Perspective Stock please use our How to Invest in Perspective Therapeutics guide.At this time, Perspective Therapeutics' Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 15.35 in 2024, whereas Tax Provision is likely to drop (2.5 M) in 2024.
 2021 2022 2023 2024 (projected)
Total Operating Expenses18.2M17.4M42.4M44.5M
Cost Of Revenue6.2M5.5M4.9M4.2M

Perspective Therapeutics fundamental ratios Correlations

0.60.750.820.990.76-0.24-0.48-0.870.820.520.780.530.330.150.790.910.780.960.810.57-0.340.960.42-0.090.86
0.60.960.930.480.83-0.10.31-0.660.92-0.270.96-0.34-0.13-0.30.960.50.640.620.94-0.3-0.750.740.34-0.010.54
0.750.960.980.640.88-0.040.13-0.720.97-0.090.99-0.15-0.11-0.320.980.660.720.730.98-0.11-0.750.850.290.030.71
0.820.930.980.720.9-0.060.07-0.81.0-0.020.99-0.050.0-0.170.990.740.820.811.00.0-0.710.910.31-0.10.78
0.990.480.640.720.68-0.26-0.6-0.840.730.630.670.650.40.230.690.90.720.940.710.69-0.220.920.42-0.080.84
0.760.830.880.90.68-0.13-0.03-0.760.90.080.890.00.24-0.170.90.80.730.750.90.05-0.590.850.35-0.090.73
-0.24-0.1-0.04-0.06-0.26-0.130.20.5-0.1-0.19-0.1-0.23-0.53-0.39-0.11-0.36-0.13-0.44-0.07-0.24-0.49-0.26-0.97-0.11-0.21
-0.480.310.130.07-0.6-0.030.20.260.07-1.00.12-0.95-0.58-0.320.11-0.420.02-0.40.08-0.93-0.38-0.29-0.15-0.2-0.25
-0.87-0.66-0.72-0.8-0.84-0.760.50.26-0.83-0.3-0.77-0.31-0.44-0.27-0.78-0.88-0.79-0.97-0.8-0.370.23-0.94-0.680.12-0.83
0.820.920.971.00.730.9-0.10.07-0.83-0.020.99-0.030.01-0.120.980.760.850.821.00.02-0.680.920.35-0.130.81
0.52-0.27-0.09-0.020.630.08-0.19-1.0-0.3-0.02-0.070.950.590.3-0.060.460.010.44-0.030.930.340.330.160.20.28
0.780.960.990.990.670.89-0.10.12-0.770.99-0.07-0.12-0.04-0.230.990.690.770.771.0-0.07-0.720.880.35-0.030.73
0.53-0.34-0.15-0.050.650.0-0.23-0.95-0.31-0.030.95-0.120.560.49-0.090.480.140.46-0.060.990.430.330.18-0.010.35
0.33-0.13-0.110.00.40.24-0.53-0.58-0.440.010.59-0.040.560.480.020.480.080.420.010.580.390.290.49-0.050.19
0.15-0.3-0.32-0.170.23-0.17-0.39-0.32-0.27-0.120.3-0.230.490.48-0.190.20.290.26-0.180.530.490.110.31-0.690.06
0.790.960.980.990.690.9-0.110.11-0.780.98-0.060.99-0.090.02-0.190.70.770.780.99-0.05-0.710.890.36-0.060.72
0.910.50.660.740.90.8-0.36-0.42-0.880.760.460.690.480.480.20.70.810.920.730.54-0.190.910.51-0.160.93
0.780.640.720.820.720.73-0.130.02-0.790.850.010.770.140.080.290.770.810.790.80.22-0.440.840.32-0.550.85
0.960.620.730.810.940.75-0.44-0.4-0.970.820.440.770.460.420.260.780.920.790.80.51-0.230.970.61-0.10.87
0.810.940.981.00.710.9-0.070.08-0.81.0-0.031.0-0.060.01-0.180.990.730.80.8-0.02-0.710.910.32-0.080.76
0.57-0.3-0.110.00.690.05-0.24-0.93-0.370.020.93-0.070.990.580.53-0.050.540.220.51-0.020.390.380.21-0.070.41
-0.34-0.75-0.75-0.71-0.22-0.59-0.49-0.380.23-0.680.34-0.720.430.390.49-0.71-0.19-0.44-0.23-0.710.39-0.440.290.07-0.3
0.960.740.850.910.920.85-0.26-0.29-0.940.920.330.880.330.290.110.890.910.840.970.910.38-0.440.47-0.120.88
0.420.340.290.310.420.35-0.97-0.15-0.680.350.160.350.180.490.310.360.510.320.610.320.210.290.470.090.39
-0.09-0.010.03-0.1-0.08-0.09-0.11-0.20.12-0.130.2-0.03-0.01-0.05-0.69-0.06-0.16-0.55-0.1-0.08-0.070.07-0.120.09-0.13
0.860.540.710.780.840.73-0.21-0.25-0.830.810.280.730.350.190.060.720.930.850.870.760.41-0.30.880.39-0.13
Click cells to compare fundamentals

Perspective Therapeutics Account Relationship Matchups

Perspective Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets8.7M70.4M64.4M58.1M97.9M102.8M
Other Current Liab(321K)89K1.0M(406K)9.5M9.9M
Total Current Liabilities1.6M1.8M2.3M2.7M15.7M16.4M
Total Stockholder Equity5.7M67.4M61.3M54.6M75.2M78.9M
Property Plant And Equipment Net2.7M2.7M2.5M2.1M6.3M6.6M
Net Debt(1.4M)(63.1M)(55.4M)(21.0M)(6.7M)(7.0M)
Retained Earnings(87.9M)(91.3M)(98.6M)(105.9M)(152.4M)(160.1M)
Accounts Payable654K730K966K1.5M6.1M6.4M
Cash2.4M63.8M55.9M21.0M9.2M10.4M
Non Current Assets Total3.2M3.1M5.1M2.3M81.1M85.1M
Cash And Short Term Investments2.4M63.8M55.9M43.8M9.2M12.1M
Net Receivables2.0M2.0M1.6M1.4M1.2M986.9K
Common Stock Shares Outstanding67.6M103.8M14.2M142.1M26.8M34.7M
Liabilities And Stockholders Equity8.7M70.4M64.4M58.1M97.9M102.8M
Non Current Liabilities Total621K1.4M1.2M896K7.0M7.4M
Inventory645K980K1.4M1.4M1.6M1.7M
Other Current Assets426K481K27K6.7M6.4M6.7M
Other Stockholder Equity93.6M158.6M159.7M160.4M227.3M244.4M
Total Liab3.0M3.0M3.2M3.4M22.7M23.8M
Total Current Assets5.5M67.3M59.3M53.2M16.8M14.5M
Common Stock55K67K69K142K282K296.1K
Non Currrent Assets Other137K76K2.5M(2.3M)182K294.6K
Intangible Assets138K130K107K86K50.4M52.9M
Net Invested Capital5.7M67.4M61.3M76.9M88.4M48.6M
Net Working Capital3.9M65.5M57.1M1.2M1.3M1.3M
Property Plant And Equipment Gross10.3M10.0M10.0M7.0M6.3M5.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Perspective Stock Analysis

When running Perspective Therapeutics' price analysis, check to measure Perspective Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Perspective Therapeutics is operating at the current time. Most of Perspective Therapeutics' value examination focuses on studying past and present price action to predict the probability of Perspective Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Perspective Therapeutics' price. Additionally, you may evaluate how the addition of Perspective Therapeutics to your portfolios can decrease your overall portfolio volatility.